CX101

CX101 is a preclinical small molecule drug candidate being developed by CureX Biopharma for the treatment of colorectal cancer. It is designed to target the DNA mismatch repair (MMR) pathway, specifically focusing on the proteins MSH2, MSH3, and MSH6. These proteins are critical components of the MutS complexes (MutSα and MutSβ) that recognize and initiate the repair of DNA base-base mismatches and insertion/deletion loops. By modulating these targets, CX101 aims to exploit or correct deficiencies in the DNA repair mechanisms often found in colorectal malignancies, potentially offering a targeted therapeutic approach for patients with specific genetic profiles, such as those with microsatellite instability.